TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. uri icon

authors

  • Aldoss, Ibrahim
  • Blackmon, Amanda
  • Otoukesh, Salman
  • Sandhu, Karamjeet
  • Ball, Brian
  • Arslan, Shukaib
  • Andrew Artz, MD, MS
  • Amanam, Idoroenyi
  • Al Malki, Monzr M
  • Salhotra, Amandeep
  • Kovacsovics, Tibor
  • Li, Shanpeng
  • Murphy, Lindsey
  • Afkhami, Michelle
  • Ngo, Dat
  • Tinajero, Jose
  • Gu, Zhaohui
  • Becker, Pamela S
  • Nakamura, Ryotaro
  • Stein, Anthony
  • Marcucci, Guido
  • Forman, Stephen J
  • Zhang, Jianying
  • Pullarkat, Vinod
  • Clark, Mary C
  • Agrawal, Vaibhav
  • Pourhassan, Hoda
  • Koller, Paul
  • Aribi, Ahmed
  • Ali, Haris

publication date

  • May 13, 2025